Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 5, 2026

Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin

View original at seekingalpha.com
Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin Earnings Call Insights: Samsara (IOT) Q1 fiscal 2027 MANAGEMENT VIEW * "Samsara delivered a strong start to FY '27, with another quarter of durable and efficient growth" (CEO Sanjit Biswas), including: "We ended Q1 with ne…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Samsara uses coding bots and agents internally and is automating workflows

    60% confidence
  • In Q1, Samsara added 169 customers with $100,000+ ARR and 15 customers with $1 million+ ARR

    60% confidence
  • For full year FY '27, Samsara expects revenue between $2.005 billion and $2.013 billion

    60% confidence
  • Q2 non-GAAP EPS expected to be between $0.15 and $0.16

    60% confidence
  • Samsara has only been offering Connected Asset Maintenance for a few quarters now

    60% confidence
  • Customer expansions are more driven by more assets or licenses on the same product

    60% confidence
  • In May, Samsara gathered hundreds of public sector customers at Go Beyond event in Chicago, introducing Waste Intelligence, Ground Intelligence, and Ridership Management

    60% confidence
  • Samsara ended Q1 with nearly $2 billion in ARR, growing 30% year-over-year

    60% confidence
  • Waste Intelligence is monetized as additional SKUs

    60% confidence
  • Q1 strength was driven by strength in emerging products

    60% confidence
  • At some point Samsara may offer a consumption-based pricing model for agents

    60% confidence
  • Q1 was Samsara's third consecutive quarter of GAAP profitability

    60% confidence
  • There is no unusual seasonality behind the modest-looking Q2 guidance step despite the raised full-year guide

    60% confidence
  • Samsara delivered a strong start to FY '27, with another quarter of durable and efficient growth

    60% confidence
  • Samsara signed 11 $1 million-plus net new ACV transactions in Q1

    60% confidence
  • Samsara raised the full-year non-GAAP operating margin target from 19% to 20%

    60% confidence
  • 96% of $100,000-plus ARR customers subscribe to two or more products

    60% confidence
  • For Q2, Samsara expects revenue between $482 million and $484 million

    60% confidence
  • Samsara is emphasizing LTM (last 12 months) figures to reduce perceived volatility from large deal timing

    60% confidence
  • Q1 net new ARR was $101 million

    60% confidence
  • Samsara added $101 million in net new ARR in Q1

    60% confidence
  • Non-GAAP operating margin was 19% in Q1

    60% confidence
  • Memory market visibility isn't as good as it has been in the past

    60% confidence
  • GAAP EPS would still be positive excluding the Motive arbitration award

    60% confidence
  • Nothing about Q1 strength stands out as one-time in nature

    60% confidence
  • Europe contributed a record amount of net new ACV mix

    60% confidence
  • Samsara hasn't had a problem stocking component supply despite tighter memory markets

    60% confidence
  • Q2 non-GAAP operating margin expected to be 18%

    60% confidence
  • The Supreme Court ruling is good for Samsara's business overall

    60% confidence
  • Samsara now has over $1.2 billion in ARR from customers spending $100,000 or more, growing 37% year-over-year

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin — Source | Via News | ViaNews EU